Welireg® (belzutifan) – New indication
December 14, 2023 - Merck announced the FDA approval of Welireg (belzutifan), for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Top